論文 - 詳細
| RRC ID | 45104 |
|---|---|
| 著者 | Cortes-Dericks L, Froment L, Boesch R, Schmid RA, Karoubi G. |
| タイトル | Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDH(high)CD44(+) phenotype and sphere-forming capacity. |
| ジャーナル | BMC Cancer |
| Abstract |
BACKGROUND:Conventional chemotherapy in malignant pleural mesothelioma (MPM) has minimal impact on patient survival due to the supposed chemoresistance of cancer stem cells (CSCs). We sought to identify a sub-population of chemoresistant cells by using putative CSC markers, aldehyde dehydrogenase (ALDH) and CD44 in three MPM cell lines; H28, H2052 and Meso4. METHODS:The Aldefluor assay was used to measure ALDH activity and sort ALDH(high) and ALDH(low) cells. Drug-resistance was evaluated by cell viability, anchorage-independent sphere formation, flow-cytometry and qRT-PCR analyses. RESULTS:The ALDH(high) - and ALDH(low) -sorted fractions were able to demonstrate phenotypic heterogeneity and generate spheres, the latter being less efficient, and both showed an association with CD44. Cis- diamminedichloroplatinum (II) (cisplatin) treatment failed to reduce ALDH activity and conferred only a short-term inhibition of sphere generation in both ALDH(high) and ALDH(low) fractions of the three MPM cell lines. Induction of drug sensitivity by an ALDH inhibitor, diethylaminobenzaldehyde (DEAB) resulted in significant reductions in cell viability but not a complete elimination of the sphere-forming cells, suggestive of the presence of a drug-resistant subpopulation. At the transcript level, the cisplatin + DEAB-resistant cells showed upregulated mRNA expression levels for ALDH1A2, ALDH1A3 isozymes and CD44 indicating the involvement of these markers in conferring chemoresistance in both ALDH(high) and ALDH(low) fractions of the three MPM cell lines. CONCLUSIONS:Our study shows that ALDH(high) CD44(+) cells are implicated in conveying tolerance to cisplatin in the three MPM cell lines. The combined use of CD44 and ALDH widens the window for identification and targeting of a drug-resistant population which may improve the current treatment modalities in mesothelioma. |
| 巻・号 | 14 |
| ページ | 304 |
| 公開日 | 2014-4-30 |
| DOI | 10.1186/1471-2407-14-304 |
| PII | 1471-2407-14-304 |
| PMID | 24884875 |
| PMC | PMC4021184 |
| MeSH | Aldehyde Dehydrogenase 1 Family Aldehyde Oxidoreductases / biosynthesis* Biomarkers, Tumor Cell Line, Tumor Cell Survival / drug effects Cisplatin / administration & dosage* Drug Resistance, Neoplasm / genetics Humans Hyaluronan Receptors / genetics Hyaluronan Receptors / metabolism* Lung Neoplasms / drug therapy Lung Neoplasms / genetics* Lung Neoplasms / pathology Mesothelioma / drug therapy Mesothelioma / genetics* Mesothelioma / pathology Mesothelioma, Malignant Neoplastic Stem Cells / metabolism Phenotype Retinal Dehydrogenase / biosynthesis* |
| IF | 3.15 |
| 引用数 | 49 |
| WOS 分野 | ONCOLOGY |
| リソース情報 | |
| ヒト・動物細胞 | ACC-MESO-4(RCB2293) |